1 / 3

Mutations somatiques de HER2 (n = 25)

780-781insGSP. def. 755-759*. L755W. D769H. D769Y. L755S. V777L. I767M. G309A. G309E. S310F. G1201V. Kinase. ECD. Tail. TM. JM. 0. 200. 400. 600. 800. 1000. 1200. V842I. R678Q. Y835F. R896C. Mutations somatiques de HER2 (n = 25). 1 cercle rouge : 1 patient.

gabriel-johnson
Download Presentation

Mutations somatiques de HER2 (n = 25)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 780-781insGSP def. 755-759* L755W D769H D769Y L755S V777L I767M G309A G309E S310F G1201V Kinase ECD Tail TM JM 0 200 400 600 800 1000 1200 V842I R678Q Y835F R896C Mutationssomatiques de HER2 (n = 25) 1 cercle rouge : 1 patient. D’après Bose R et al., abstr. S5-6 actualisé

  2. Inhibition de la croissance cellulaire par nératinib et lapatinib • Le nératinib semble plus puissant et il est actif dans toutes les mutations de HER2 D’après Bose R et al., abstr. S5-6 actualisé

  3. Amplification du gène HER2 négative Stade IV Séquençage de l’ADN tumoral Mutation absente Mutation présente Inéligible Nératinib 240 mg/j J1-J28 Étude de phase II du nératinib chez les patientes mutées HER2 D’après Bose R et al., abstr. S5-6 actualisé

More Related